Administrative Core

本申请代表了丹娜-法伯/哈佛癌症中心前列腺癌项目（DF/HCC）的前列腺癌卓越研究专业项目（SPORE）的更新申请。自2002年以来，DF/HCC前列腺癌孢子一直得到持续资助。DF/HCC由以下机构组成：丹娜-法伯癌症研究所；哈佛医学院；哈佛大学公共卫生学院；贝斯以色列女执事医疗中心；布里格姆妇女医院；马萨诸塞州总医院；以及波士顿儿童医院除了DF/HCC的机构外，布罗德研究所也是该资助的合作机构。DF/HCC前列腺癌孢子在DFCI有其行政基础。自DF/HCC前列腺癌项目和SPORE成立以来一直领导该项目的Philip Kantoff博士与DFCI的实验室科学家William Hahn博士和BIDMC的实验室科学家Steven Balk博士共同担任董事。Kantoff博士直接向DF/HCC主任兼DFCI总裁Edward Benz博士汇报。DF/HCC前列腺癌孢子拥有广泛而深厚的人才基础，并有广泛的机构承诺。作为DF/HCC的一部分，我们利用了庞大的患者群体和尖端技术。我们提出了5个项目来解决前列腺癌的关键问题，包括：1)了解肥胖影响前列腺癌死亡率的机制；2)剖析Gleason 7前列腺癌的临床异质性；3)阐明EZH2信号通路的重要性；4)了解基因组变化对雄激素剥夺治疗和侵袭性前列腺癌的抗性的作用对二次激素治疗产生抗药性的机制。这五个项目得到了三个核心的支持，一个是行政核心，一个是生物统计学和计算生物学核心，一个是组织和病理学核心。我们还有一个非常成功的职业发展计划，选择有才华的医生科学家并指导他们独立，以及一个发展项目计划，为孢子的未来产生新的想法。

This application represents a renewal application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been continuously funded since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute; Harvard Medical School; Harvard School of Public Health; Beth Israel-Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute is a collaborating institution in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 5 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) elucidating the importance of the EZH2 signaling pathway 4) understanding the role that genomic change has on resistance to androgen deprivation therapy and on aggressive prostate cancer and finally 5) understanding the mechanism that underlie resistance to secondary forms of hormonal therapy. The five projects are supported by three Cores, an Administrative, a Biostatistics and Computional Biology and a Tissue and Pathology Core. We also have a highly successful Career Development Progam that selects talented phycian scientists and mentors them to independence and a Developmental Projects Program that generates new ideas for the SPORE in the future.